Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6113047rdf:typepubmed:Citationlld:pubmed
pubmed-article:6113047lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0025663lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0027627lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0220908lld:lifeskim
pubmed-article:6113047lifeskim:mentionsumls-concept:C0205485lld:lifeskim
pubmed-article:6113047pubmed:issue2lld:pubmed
pubmed-article:6113047pubmed:dateCreated1981-8-27lld:pubmed
pubmed-article:6113047pubmed:abstractTextTen tumor markers were measured in serum or urine at approximately three month intervals in patients with breast cancer following mastectomy but before development of overt metastatic disease. In 23 patients who later had metastases, only three markers, alkaline phosphatase, carcinoembryonic antigen (CEA), and gamma-glutamyl transpeptidase (gamma-GT) were consistently abnormal prior to the development of detectable metastases in more than one patient. In half the patients, a "lead interval" of three months or more was obtained using these three markers and little advantage was obtained by the addition of any other biochemical marker. The value of these three measurements was then assessed in a larger group of patients and compared with other tests for metastases. Alkaline phosphatase, CEA, gamma-GT, clinical examination, and chest x-ray were the best indices of the metastatic state in breast cancer, being collectively abnormal in 98% of patients at first presentation with metastases. The authors recommend screening patients postoperatively with these five tests for metastases; more detailed tests should only be carried out if results of one or more these are abnormal.lld:pubmed
pubmed-article:6113047pubmed:languageenglld:pubmed
pubmed-article:6113047pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6113047pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6113047pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6113047pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6113047pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6113047pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6113047pubmed:statusMEDLINElld:pubmed
pubmed-article:6113047pubmed:monthJullld:pubmed
pubmed-article:6113047pubmed:issn0008-543Xlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:JonesMMlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:GehrkeC WCWlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:KeyserJ WJWlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:NevilleA MAMlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:StimsonW HWHlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:WorwoodMMlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:PowlesT JTJlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:GazetJ CJClld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:FordH THTlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:CoombesR CRClld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:PatelSSlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:AbbottMMlld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:MitchellP EPElld:pubmed
pubmed-article:6113047pubmed:authorpubmed-author:McKinnaAAlld:pubmed
pubmed-article:6113047pubmed:issnTypePrintlld:pubmed
pubmed-article:6113047pubmed:day15lld:pubmed
pubmed-article:6113047pubmed:volume48lld:pubmed
pubmed-article:6113047pubmed:ownerNLMlld:pubmed
pubmed-article:6113047pubmed:authorsCompleteYlld:pubmed
pubmed-article:6113047pubmed:pagination310-5lld:pubmed
pubmed-article:6113047pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:meshHeadingpubmed-meshheading:6113047-...lld:pubmed
pubmed-article:6113047pubmed:year1981lld:pubmed
pubmed-article:6113047pubmed:articleTitleScreening for metastases in breast cancer: an assessment of biochemical and physical methods.lld:pubmed
pubmed-article:6113047pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6113047lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6113047lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6113047lld:pubmed